Products

Description

GLIMET^® / GLIMET^® DS is a novel combination product combining the vasoprotective sulphonylurea Glipizide, with the metabolic regulator Metformin, presented in two variable combinations to facilitate dose titration.

Glipizide is a second generation sulphonylurea. Glipizide offers Insulin-on-Demand to control hyperglycaemia without causing beta-cell fatigue (by constant pancreatic stimulation as seen with long acting drugs). In addition, it provides unmatched circulatory benefits in those on long term therapy.

Metformin is the only world-wide accepted drug of the biguanide family for the management of diabetes. Metformin acts only in the presence of insulin. Its main site of action is believed to be the receptors and post-receptor effector site inside cells, to increase glucose utilization and glycogenesis while preventing neo-glucogenesis by the liver. Therapy of Type 2 diabetes with Metformin has shown additional vascular benefits in the form of lower diastolic blood pressure, lower thrombotic risks, and lower blood viscosity.

GLIMET^® combines the insulin-on-demand and capillary-normalizing hypoglycaemic activity of Glipizide, with the insulin-activity normalizing action and metabolic regularizing activity of Metformin, to provide an unprecedented level of benefits in the oral therapy of Type 2 diabetes.

GLIMET^® and GLIMET^® DS TABLETS

(ORAL ANTI-HYPERGLYCEMIC AGENT)

Composition

GLIMET^®

Each uncoated tablet contains:
Glipizide I.P.................................................................... 2.5 mg.
Metformin Hydrochloride I.P. ..........................................250 mg.
Excipients ……………………………………………………..q.s.

GLIMET^® DS

Each uncoated tablet contains:
Glipizide I.P. .................................................................. 5 mg.
Metformin Hydrochloride I.P.......................................... 500 mg.
Excipients …………………………………………………… q.s.
Colour: Lake of Quinoline Yellow (C.I. No. 47005)